IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn's disease patients (2018) Schmitt H, Billmeier U, Dieterich W, Rath T, Sonnewald S, Reid S, Hirschmann S, et al. Conference contribution Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammation (2018) Zundler S, Becker E, Spocinska M, Parga-Vidal L, Stark R, Atreya R, Rath T, et al. Conference contribution IL-3 drives IL-10-secreting Tr1 cells to counteract experimental colitis (2018) Zundler S, Spocinska M, Popp V, Becker E, Atreya R, Neufert C, Atreya I, et al. Conference contribution Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease (2018) Koelink PJ, Wildenberg ME, Stitt LW, Feagan BG, Koldijk M, Van 'T Wout AB, Atreya R, et al. Journal article Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients (2018) Fischer SM, Klenske E, Schmitt H, Vitali F, Hirschmann S, Koch F, Ramming A, et al. Conference contribution Alpha 4 beta 7 Integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages (2018) Schleier L, Wiendl M, Binder MT, Atreya R, Watson A, Neufert C, Atreya I, et al. Conference contribution The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis (2018) Schmitt H, Billmeier U, Ulmschneider J, Admyre C, Knittel T, Zargari A, Neurath M, Atreya R Conference contribution Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) (2017) Siegel CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Louis E, Sebastian S, et al. Conference contribution Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided ulcerative colitis patients with moderate-to-severe disease (2017) Atreya R, Kuehbacher T, Waldner M, Hirschmann S, Drvarov O, Abu Hashem R, Maaser C, et al. Conference contribution IL-10 induction properties of the TLR-9 agonist cobitolimod - a candidate for treatment of active ulcerative colitis in late stage of clinical development (2017) Admyre C, Zargari A, Atreya R, Knittel T Conference contribution